Trial Profile

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varicella vaccine-GlaxoSmithKline (Primary) ; Hepatitis A vaccine; Measles mumps and rubella virus vaccine; Measles mumps and rubella virus vaccine; PCV 20; Pneumococcal 13-valent CRM197 vaccine conjugate; V 114; Varicella vaccines
Indications Varicella zoster virus infections
Focus Pharmacodynamics
Sponsors GSK

22 Jun 2025 Planned primary completion date changed from 13 Nov 2026 to 14 Dec 2026.
22 Jun 2025 Status changed from not yet recruiting to recruiting.
11 Feb 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com